{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Kodiak Sciences, Inc. technically bullish or bearish?
As of June 17, 2025, Kodiak Sciences, Inc. exhibits a mildly bearish trend, with daily moving averages signaling bearishness, despite some bullish indicators from weekly and monthly MACD and KST, while its year-to-date performance relative to the S&P 500 further supports this outlook.
Who are in the management team of Kodiak Sciences, Inc.?
As of March 2022, Kodiak Sciences, Inc.'s management team includes Dr. Victor Perlroth as Chairman, President, and CEO, with Mr. Robert Profusek as Lead Independent Director and several independent directors including Dr. Felix Baker, Mr. Charles Bancroft, Dr. Bassil Dahiyat, and Dr. Richard Levy.
What does Kodiak Sciences, Inc. do?
Kodiak Sciences, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for ophthalmic diseases. It has a market cap of $187.31 million and reported a net profit loss of $57 million as of March 2025.
How big is Kodiak Sciences, Inc.?
As of Jun 18, Kodiak Sciences, Inc. has a market capitalization of 187.31 million, with net sales of 0.00 million and a net profit of -190.63 million for the latest four quarters. The company reported shareholder's funds of 150.29 million and total assets of 335.58 million as of December 2024.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
